An interventional study of Synchronized Cardiac Support with the Novalung ultimate kit SCS and Control group: VA-ECMO in Cardiogenic Shock, Extracorporeal Membrane Oxygenation and ECLS, sponsored by Xenios AG. Not yet recruiting at 4 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Xenios AG (part of Fresenius Medical Care) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Shock, Cardiogenic with a site in Czechia — 4 open to participants now, 4 under way, none of them phase 3. Shock, Cardiogenic · Czechia.
Among the 11 studies in Shock, Cardiogenic with a site in Czechia, this one is the only one that started in 2027, is one of 5 with no phase, and was the 8th registered.
297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.
Browse Shock, Cardiogenic studies →4 of the 11 studies in Shock, Cardiogenic with a site in Czechia are open now. Recruiting first, the newest first:
Institute for Clinical and Experimental Medicine · Sites in Czechia
Ages 18+
University Hospital Ostrava · Sites in Czechia
Ages 18–70
4TEEN4 Pharmaceuticals GmbH · Sites in Czechia, Armenia, Belgium and 6 more countries
Ages 18–80
A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →
Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 80 across 133 interventional studies indexed under Shock, Cardiogenic.
Median enrollment 80 across the 9 interventional studies, 95 across the 2 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 11 have an industry lead sponsor. The 9 most frequent:
This study is registered under Xenios AG, one of the names counted as Fresenius Medical Care. Under that name alone:
Xenios AG is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Fresenius Medical Care has 2 studies filed under Shock, Cardiogenic — fewer than ten, so there is no comparison to draw.
2 of the studies in Shock, Cardiogenic with a site in Czechia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT068327224TEEN4 Pharmaceuticals GmbHA Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care. | 2026-12-30 |
| NCT07527156Institute for Clinical and Experimental MedicineProlonged Nasogastric Administration of Ketones in Decompensated Heart Failure | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Shock, Cardiogenic with a site in Czechia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to investigate the efficacy of the Synchronized Cardiac Support treatment with the Novalung ultimate kit SCS in patients with cardiogenic shock in comparison with patients treated with continuous flow VA-ECMO
The current study hypothesizes that SCS treatment with the Novalung ultimate kit SCS provides sufficient cardiocirculatory support compared with continuous flow VA-ECMO Patients with cardiogenic shock, requiring a VA-ECMO for circulatory stabilization will be randomized 1:1 either in the investigational group receiving Synchronized Cardiac Support treatment or continuous VA-ECMO treatment as control group.
SCS describes an electrocardiogram (ECG)-triggered pulsatile VA-ECMO based on R-wave detection. During diastole the pump speed and thus the blood flow is increased and during systole the pump flow is set to a relative minimum. This provides a mechanical circulatory support pulse with increased oxygenated blood supply during diastole. The SCS treatment will start as soon the heart rate of the patient is below 110 bpm.
SCS is used in a standard VA-ECMO configuration by two femoral single vessel cannulas according to local practice of study site The duration of the treatment can be up to 14 days.
The criteria were revised on the registry on Nov 20, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Given the exploratory nature of this randomized study, no formal sample size calculation for between-group comparisons was performed.
Assuming that about 20% of the patients will not provide serum lactate levels at 8 hours after the start of SCS treatment in the Pulse SE study, a total of 50 patients will be enrolled, with 25 patients per treatment group.
This sample size is considered adequate to allow descriptive and exploratory comparisons within and between treatment groups and to estimate effect sizes for the primary and secondary endpoints which will inform the design and sample size planning of future confirmatory studies.
The patients will be enrolled in 4 study centres across Europe.
Inclusion criteria:
Hemodynamic compromise (low cardiac output and elevated filling pressures):
Hypoperfusion:
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational group receiving Synchronized Cardiac Support treatment
Device: Synchronized Cardiac Support with the Novalung ultimate kit SCS
Control group receiving continous VA-ECMO treatment
Device: Control group: VA-ECMO
Patients receiving Synchronized Cardiac Support (SCS) treatment with the Novalung ultimate kit SCS and the Xenios 2.0 - Pulsatile flow
Patients receiving continuous flow VA-ECMO with the Novalung ultimate kit SCS and the Xenios 2.0 (Standard of care)
Cardiocirculatory stabilization and end-organ perfusion
Lactate clearance at 8 hours after randomization between SCS treatment and continuous flow VA-ECMO using the Novalung ultimate kit SCS will be assessed in an exploratory analysis via venous blood gas analysis (BGA)
Time frame: Baseline and during the ECMO treatment up to 7 days
Performance objective - Cardiocirculation
Improvement and maintenance of patients' cardiocirculation (= cardiocirculatory stabilization).
Time frame: Baseline and during the ECMO treatment up to 7 days
Performance objective - Cardiac Output
Cardiac output measured using a pulmonary artery catheter (L/min)
Time frame: Baseline and during the ECMO treatment up to 7 days
Performance objective - organ perfusion
Improvement of end-organ perfusion
Time frame: Baseline and during the ECMO treatment up to 7 days
Blood gas analysis
Assessment of blood gas parameters by arterial blood gas analysis
Time frame: Baseline and during the ECMO treatment up to 7 days
ECLS performance - blood flow
Evaluation of Xenios 2.0 performance (Extracorporeal life support - ECLS): Maintenance of blood flow (L/min)
Time frame: Baseline and during the ECMO treatment up to 7 days
ECLS performance - Pump speed
Evaluation of Xenios 2.0 performance (Extracorporeal life support - ECLS): pump speed (rpm)
Time frame: Baseline and during the ECMO treatment up to 7 days
ECLS performance - Circuit pressures
Evaluation of Xenios 2.0 performance (Extracorporeal life support - ECLS): Circuit pressures (mmHg)
Time frame: Baseline and during the ECMO treatment up to 7 days
Safety objectives
Assessment of the safety of the SCS treatment with the Novalung ultimate kit SCS in patients with cardiogenic shock in comparison with patients treated with continuous flow VA-ECMO
Time frame: Baseline and during the ECMO treatment up to 7 days
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Jan 2029, 24 months later.
Of 52 interventional studies with no phase under Shock, Cardiogenic, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's planned 24 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: start Sep 2025 → Jan 2027, primary completion Sep 2026 → Jan 2029 and completion Sep 2026 → Mar 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.